Limits of HIV treatment as prevention

Large study spotlights limits of HIV treatment as prevention.
The study, called Treatment as Prevention (TasP), began in 2012 and enrolled 28,000 people in KwaZulu-Natal, the hardest hit province in South Africa. Sponsored by the French national research agency known as ANRS, TasP tested participants in 22 separate communities, which each had an HIV prevalence of about 30%, every 6 months. Professor François Dabis, from ANRS, is the co-PI of the the ANRS 12249 TasP trial.
Pr Dabis, with more than 25 years of experience in research on HIV epidemiology and public health challenges, is a research director at the Bordeaux population health research center.

Please read the article here : Science Mag – July 20, 2016

partners

logo_ISPED logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_HONcode